RESEARCH MONOGRAPH · KDC-MN-178

Berberine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

78/100

Genuinely interesting metabolic compound, weak bioavailability is the limiting factor and DHB is the more interesting form

Berberine is one of those compounds where the mechanism is real, the metabolic effects are real, and the marketing has actually undersold the more interesting downstream story (dihydroberberine) for years.

The primary pharmacology is AMPK activation. Berberine is one of the better natural-product AMPK activators we know of, with effects on hepatic gluconeogenesis suppression, glucose uptake, lipid metabolism, and mitochondrial function. The clinical translation is meaningful, with multiple RCTs showing fasting glucose, HbA1c, and lipid improvements at 500mg three times daily, effect sizes in the same range as low-dose metformin in some head-to-head studies (most famously a small 2008 Yin trial). For a non-pharmaceutical that's a genuinely strong result.

Mechanism is multi-target. AMPK is the headline, but berberine also inhibits PCSK9 (which explains some of the LDL effects), modulates the gut microbiome substantially (with implications for the metabolic effects beyond direct AMPK activation), interferes with proprotein convertases, and inhibits respiratory complex I at higher concentrations.

Here's the bioavailability problem. Oral berberine has bioavailability around 1% or less, with most of the absorbed fraction undergoing extensive first-pass metabolism. Plasma levels are low, and the clinical effects probably come substantially through gut-resident actions (microbiome modulation, direct effects on intestinal AMPK and enterocyte signaling) rather than systemic exposure. That's underappreciated.

Dihydroberberine (DHB) is the gut-microbiome-reduced metabolite, and it has roughly 5-fold better oral bioavailability than berberine itself. Some recent supplement work has gone to DHB directly, and the limited human data so far suggests it produces comparable metabolic effects at maybe a fifth the dose. If that holds up, it's the more interesting form of the compound.

Sourcing-wise berberine hydrochloride is widely available, HPLC purity verification is standard, and reputable suppliers produce consistent material. DHB is more recent and has less established QC norms.

Safety profile is generally fine. GI tolerability is the main practical limit, and there are real interaction concerns with CYP3A4 substrates.

What we like: real AMPK activation, real metabolic signal in human trials, and DHB as a next-generation form is interesting. What we dont like: the bioavailability problem makes dose-response interpretation tricky, and the marketing rarely engages with the gut-versus-systemic question seriously.

Evidence: 75
Mechanism: 82
Reliability: 75
Safety: 75
Sourcing: 80
Value: 80
Signal: 80
Staying power: 78

Plain-language summary Intrigue 70 / 100

Berberine is an isoquinoline alkaloid from goldenseal, barberry, and other plants. It activates AMPK (the same metabolic master regulator as metformin) and lowers blood sugar and lipids. Increasingly compared to metformin in supplement contexts. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Isoquinoline alkaloid / AMPK activator

An isoquinoline alkaloid from Berberis and other plants, characterized by AMPK activation with metabolic effects comparable to metformin in some contexts.

Abstract

Berberine (CAS 2086-83-1; molecular formula C20H18NO4+; molecular weight 336.36) is an isoquinoline alkaloid present in Berberis species, Coptis chinensis (goldthread), and Hydrastis canadensis (goldenseal). The compound activates AMPK through complex I inhibition (similar mechanism to metformin) with downstream metabolic effects: improved insulin sensitivity, reduced hepatic glucose output, modest LDL cholesterol reduction. Clinical trials in T2DM show glycemic improvements comparable to metformin in some studies. The compound is also used for gut dysbiosis and SIBO based on antimicrobial activity. Bioavailability is poor (~5 percent oral); dihydroberberine has improved bioavailability. Reported research dose ranges in the literature are described in the source publications.

Mechanism of action

AMPK activator through complex I inhibition. Anti-microbial activity. Multiple metabolic and gut effects.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Yin J, et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-178

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Berberine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs